Version 1
: Received: 17 April 2021 / Approved: 19 April 2021 / Online: 19 April 2021 (12:04:31 CEST)
How to cite:
Tuba, S.; Widyati, W.; Syed Sulaiman, S.A. A Review of COVID-19 Vaccines: What Needs to Be Known and Its Expected Effect on the Human Population?. Preprints2021, 2021040468. https://doi.org/10.20944/preprints202104.0468.v1
Tuba, S.; Widyati, W.; Syed Sulaiman, S.A. A Review of COVID-19 Vaccines: What Needs to Be Known and Its Expected Effect on the Human Population?. Preprints 2021, 2021040468. https://doi.org/10.20944/preprints202104.0468.v1
Tuba, S.; Widyati, W.; Syed Sulaiman, S.A. A Review of COVID-19 Vaccines: What Needs to Be Known and Its Expected Effect on the Human Population?. Preprints2021, 2021040468. https://doi.org/10.20944/preprints202104.0468.v1
APA Style
Tuba, S., Widyati, W., & Syed Sulaiman, S.A. (2021). A Review of COVID-19 Vaccines: What Needs to Be Known and Its Expected Effect on the Human Population?. Preprints. https://doi.org/10.20944/preprints202104.0468.v1
Chicago/Turabian Style
Tuba, S., Widyati Widyati and Syed Azhar Syed Sulaiman. 2021 "A Review of COVID-19 Vaccines: What Needs to Be Known and Its Expected Effect on the Human Population?" Preprints. https://doi.org/10.20944/preprints202104.0468.v1
Abstract
The COVID-19 pandemic is a devastating blow to the entire world community and changes the order of human life. All efforts and strategies are being carried out to contain and reduce the spread of the SARS-COV-2 virus, both by tightening the health protocol and using vaccines to the public. Currently, several vaccines are available and have passed phase 3 clinical trials, such as vector vaccines (Gamaleya Sputnik V Russia, University of Oxford/AstraZeneca, CanSino, and Janssen Pharmaceutical Companies), mRNA-based vaccines (Moderna/BioNTech/Fosun Pharma/Pfizer), inactivated vaccines (SinoVac and SinoPharm from China, Covaxin from Bharat Biotech India), and adjuvanted recombinant protein nanoparticles (Novavax from the USA) are expected to be able to suppress the spread of the virus and produce a minimum of 70 percent herd-immunity in a population. Each vaccine's efficacy varies from the lowest, namely the Sinovac vaccine (CoronaVac) 50% to the highest the Novavax vaccine (NVX-Cov2373) 96% effectivity value. Moreover, further rigorous research is still being carried out for the development of an effective and efficient vaccine.
Copyright:
This is an open access article distributed under the Creative Commons Attribution License which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
